Jonathan Whisenant, MD
Hematology & Oncology · Salt Lake City, UTNPI 1861441974
Payments from drug & device makers
Across 85 payments — averaging $2896.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$89K
- Taiho Oncology, Inc.$59K
- Agios Pharmaceuticals, Inc.$43K
- Incyte Corporation$31K
- Blueprint Medicines Corporation$11K
- Ipsen Biopharmaceuticals, Inc$4K
- plus $9K from 18 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 8 | $88,884 |
| Taiho Oncology, Inc. | 2 | $58,843 |
| Agios Pharmaceuticals, Inc. | 12 | $43,157 |
| Incyte Corporation | 6 | $31,331 |
| Blueprint Medicines Corporation | 2 | $11,122 |
| Ipsen Biopharmaceuticals, Inc | 9 | $4,316 |
| AstraZeneca | 3 | $3,366 |
| Servier Pharmaceuticals LLC | 2 | $1,971 |
| Cornerstone Specialty Network LLC | 8 | $1,500 |
| Daiichi Sankyo Inc. | 9 | $1,035 |
| Johnson & Johnson | 4 | $170 |
| Beigene USA, Inc. | 5 | $125 |
| Bristol Myers Squibb | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 1 | $52 |
| GSK | 2 | $37 |
| Beone Medicines USA, Inc. | 1 | $35 |
| Novartis | 1 | $32 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Mirati Therapeutics, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Gilead | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Pfizer | 1 | $13 |
How this compares
$246,187 in reported general payments places this provider in the 65th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Salt Lake City
- Neeraj AgarwalSalt Lake City$32.4M
- Douglas SborovSalt Lake City$7.8M
- Tsewang TashiSalt Lake City$6.7M
- Benjamin MaughanSalt Lake City$5.6M
- Daanish HodaSalt Lake City$2.9M
- Shiven PatelSalt Lake City$2.9M
- Vaia FlorouSalt Lake City$2.3M
- Theresa WernerSalt Lake City$1.9M
- Heloisa SoaresSalt Lake City$1.7M
- Sunil SharmaSalt Lake City$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.